Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANTOS OGTT substudy in type 2 diabetes mellitus
2012-003011-58Phase 3Terminated
- Sponsor
- Novartis
- Start
- Oct 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), atherosclerosis and cardiac morbidity comparing Canakinumab with Placebo (2 arms). Started Oct 2012; status: terminated.
02
Drugs
canakinumab
03
Conditions
type 2 diabetes mellitus (T2DM)atherosclerosiscardiac morbidity
Beyond the preview
Go deeper on 2012-003011-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003011-58.